More like the ROI in terms of revenues for Pfizer wasn't worth it. What maybe $70 million in yearly revenue for an ER in an already crowded ER Oxy opioid market wasn't worth the time or effort.
90% of opioids prescribed are IR opioids. 10 percent ER opioids and 2 percent of that is ADT opioids. Eli 200 will make a killing compared to Remoxy.
News 
Market Data 
Discover 
